Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27872502 | 0.68 | CYP2D6 (0.31) | — | |
| SCHEMBL18096005 | 0.67 | SMN1; SMN2 (0.46) | CRBN | |
| SCHEMBL28045107 | 0.62 | — | — | |
| SCHEMBL15774998 | 0.61 | CRBN (0.30) | CRBN | |
| Succinimide SCHEMBL2221415 | 0.60 | CRBN (0.55) | CRBN | |
| Succinimide SCHEMBL30823560 | 0.60 | CRBN (0.55) | CRBN | |
| SCHEMBL28545538 | 0.60 | CRBN (0.74) | CRBN | |
| Acetamide SCHEMBL27447869 | 0.59 | — | — | |
| 2-Pyrrolidone SCHEMBL28849488 | 0.59 | OR51E2 (0.62) | CRBN | |
| 2-Pyrrolidone SCHEMBL27739471 | 0.59 | OR51E2 (0.62) | CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741479-B2 | Urea inhibitors of MAP kinases | LOCUS PHARMACEUTICALS, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| EP-1828169-A2 | UREA INHIBITORS OF MAP KINASES | Locus Pharmaceuticals, Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20060167247-A1 | Urea inhibitors of MAP kinases | LOCUS PHARMACEUTICALS, INC. | 2006-07-27 | — | — | US | disclosed |
| WO-2006062982-A2 | UREA INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167247-A1 | Urea inhibitors of MAP kinases | MAPK1, MAP3K1, MAP3K20 | CRBN 2698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.